ZA200608239B - Therapeutic combination for treatment of Alzheimers disease - Google Patents
Therapeutic combination for treatment of Alzheimers disease Download PDFInfo
- Publication number
- ZA200608239B ZA200608239B ZA200608239A ZA200608239A ZA200608239B ZA 200608239 B ZA200608239 B ZA 200608239B ZA 200608239 A ZA200608239 A ZA 200608239A ZA 200608239 A ZA200608239 A ZA 200608239A ZA 200608239 B ZA200608239 B ZA 200608239B
- Authority
- ZA
- South Africa
- Prior art keywords
- active
- pharmaceutically acceptable
- alzheimer
- disease
- acetylcholine esterase
- Prior art date
Links
- 208000024827 Alzheimer disease Diseases 0.000 title claims description 69
- 230000001225 therapeutic effect Effects 0.000 title description 7
- 150000003839 salts Chemical class 0.000 claims description 75
- 229940100578 Acetylcholinesterase inhibitor Drugs 0.000 claims description 62
- 239000008194 pharmaceutical composition Substances 0.000 claims description 52
- 241000124008 Mammalia Species 0.000 claims description 49
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims description 38
- 239000003085 diluting agent Substances 0.000 claims description 38
- 239000003937 drug carrier Substances 0.000 claims description 36
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 claims description 28
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 claims description 28
- 229960005370 atorvastatin Drugs 0.000 claims description 28
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 claims description 26
- 230000000694 effects Effects 0.000 claims description 13
- OJRHUICOVVSGSY-RXMQYKEDSA-N (2s)-2-chloro-3-methylbutan-1-ol Chemical compound CC(C)[C@H](Cl)CO OJRHUICOVVSGSY-RXMQYKEDSA-N 0.000 claims description 12
- 229960001770 atorvastatin calcium Drugs 0.000 claims description 12
- 229960003530 donepezil Drugs 0.000 claims description 11
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 230000006641 stabilisation Effects 0.000 claims description 7
- 238000011105 stabilization Methods 0.000 claims description 7
- 230000000051 modifying effect Effects 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 5
- 230000000087 stabilizing effect Effects 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 4
- 230000008859 change Effects 0.000 claims description 3
- 208000024891 symptom Diseases 0.000 claims description 3
- XXAXVMUWHZHZMJ-UHFFFAOYSA-N Chymopapain Chemical compound OC1=CC(S(O)(=O)=O)=CC(S(O)(=O)=O)=C1O XXAXVMUWHZHZMJ-UHFFFAOYSA-N 0.000 claims 1
- 108090001069 Chymopapain Proteins 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 description 64
- 150000001875 compounds Chemical class 0.000 description 40
- 238000000034 method Methods 0.000 description 28
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 24
- 201000010099 disease Diseases 0.000 description 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 20
- 239000002552 dosage form Substances 0.000 description 15
- 235000012000 cholesterol Nutrition 0.000 description 10
- 238000002560 therapeutic procedure Methods 0.000 description 10
- 101710137189 Amyloid-beta A4 protein Proteins 0.000 description 8
- 101710151993 Amyloid-beta precursor protein Proteins 0.000 description 8
- 102100022704 Amyloid-beta precursor protein Human genes 0.000 description 8
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 description 8
- 206010012289 Dementia Diseases 0.000 description 7
- 230000032683 aging Effects 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 210000004556 brain Anatomy 0.000 description 5
- 150000002632 lipids Chemical class 0.000 description 5
- 238000012545 processing Methods 0.000 description 5
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- XSVMFMHYUFZWBK-NSHDSACASA-N Rivastigmine Chemical compound CCN(C)C(=O)OC1=CC=CC([C@H](C)N(C)C)=C1 XSVMFMHYUFZWBK-NSHDSACASA-N 0.000 description 3
- ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 description 3
- 229960001685 tacrine Drugs 0.000 description 3
- YLJREFDVOIBQDA-UHFFFAOYSA-N tacrine Chemical compound C1=CC=C2C(N)=C(CCCC3)C3=NC2=C1 YLJREFDVOIBQDA-UHFFFAOYSA-N 0.000 description 3
- 102000002659 Amyloid Precursor Protein Secretases Human genes 0.000 description 2
- 108010043324 Amyloid Precursor Protein Secretases Proteins 0.000 description 2
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 2
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 2
- 239000006053 animal diet Substances 0.000 description 2
- 229940039856 aricept Drugs 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 208000010877 cognitive disease Diseases 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 229940108366 exelon Drugs 0.000 description 2
- 229960004844 lovastatin Drugs 0.000 description 2
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 2
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 2
- 230000002981 neuropathic effect Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- ZGGHKIMDNBDHJB-NRFPMOEYSA-M (3R,5S)-fluvastatin sodium Chemical compound [Na+].C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 ZGGHKIMDNBDHJB-NRFPMOEYSA-M 0.000 description 1
- CABVTRNMFUVUDM-VRHQGPGLSA-N (3S)-3-hydroxy-3-methylglutaryl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C[C@@](O)(CC(O)=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 CABVTRNMFUVUDM-VRHQGPGLSA-N 0.000 description 1
- KJTLQQUUPVSXIM-ZCFIWIBFSA-M (R)-mevalonate Chemical compound OCC[C@](O)(C)CC([O-])=O KJTLQQUUPVSXIM-ZCFIWIBFSA-M 0.000 description 1
- 208000037259 Amyloid Plaque Diseases 0.000 description 1
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 1
- 102000013918 Apolipoproteins E Human genes 0.000 description 1
- 108010025628 Apolipoproteins E Proteins 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- KJTLQQUUPVSXIM-UHFFFAOYSA-N DL-mevalonic acid Natural products OCCC(O)(C)CC(O)=O KJTLQQUUPVSXIM-UHFFFAOYSA-N 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 description 1
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 1
- 206010054880 Vascular insufficiency Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000003941 amyloidogenesis Effects 0.000 description 1
- 206010002022 amyloidosis Diseases 0.000 description 1
- 239000003529 anticholesteremic agent Substances 0.000 description 1
- 229940127226 anticholesterol agent Drugs 0.000 description 1
- FQCKMBLVYCEXJB-MNSAWQCASA-L atorvastatin calcium Chemical compound [Ca+2].C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC([O-])=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1.C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC([O-])=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 FQCKMBLVYCEXJB-MNSAWQCASA-L 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 229960005110 cerivastatin Drugs 0.000 description 1
- SEERZIQQUAZTOL-ANMDKAQQSA-N cerivastatin Chemical compound COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 SEERZIQQUAZTOL-ANMDKAQQSA-N 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000006999 cognitive decline Effects 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 229960003765 fluvastatin Drugs 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 229960003980 galantamine Drugs 0.000 description 1
- ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 description 1
- 230000036433 growing body Effects 0.000 description 1
- 235000009200 high fat diet Nutrition 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 229940002661 lipitor Drugs 0.000 description 1
- 208000027061 mild cognitive impairment Diseases 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000007137 neurofibrillary pathology Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 229960002965 pravastatin Drugs 0.000 description 1
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229960004136 rivastigmine Drugs 0.000 description 1
- 229960000672 rosuvastatin Drugs 0.000 description 1
- BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 229960002855 simvastatin Drugs 0.000 description 1
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 208000023577 vascular insufficiency disease Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US56214104P | 2004-04-14 | 2004-04-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200608239B true ZA200608239B (en) | 2008-06-25 |
Family
ID=34963723
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200608239A ZA200608239B (en) | 2004-04-14 | 2006-10-03 | Therapeutic combination for treatment of Alzheimers disease |
Country Status (14)
| Country | Link |
|---|---|
| EP (1) | EP1737539A1 (enExample) |
| JP (1) | JP2007532624A (enExample) |
| KR (1) | KR20060133008A (enExample) |
| CN (1) | CN1960781A (enExample) |
| AU (1) | AU2005232447A1 (enExample) |
| BR (1) | BRPI0509881A (enExample) |
| CA (1) | CA2562069A1 (enExample) |
| IL (1) | IL178120A0 (enExample) |
| MX (1) | MXPA06011969A (enExample) |
| NO (1) | NO20065196L (enExample) |
| RU (1) | RU2006136361A (enExample) |
| TW (1) | TW200533341A (enExample) |
| WO (1) | WO2005099823A1 (enExample) |
| ZA (1) | ZA200608239B (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI432195B (zh) * | 2007-10-03 | 2014-04-01 | Kowa Co | 神經細胞死亡抑制劑 |
| JP7059192B2 (ja) * | 2016-02-11 | 2022-04-25 | シグマテラ・ソシエテ・パ・アクシオンス・シンプリフィエ | 神経変性疾患の治療に使用するためのイグメシン |
| WO2020252475A1 (en) * | 2019-06-14 | 2020-12-17 | Atiba Joshua O | Triple pharmaceutical composition for proteinaceous infection |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020028826A1 (en) * | 2000-06-15 | 2002-03-07 | Robl Jeffrey A. | HMG-CoA reductase inhibitors and method |
| ATE331523T1 (de) * | 2002-04-02 | 2006-07-15 | Janssen Pharmaceutica Nv | Statin-therapie zur verbesserung der aufrechterhaltung der kognitiven funktion |
| AU2003298514A1 (en) * | 2002-05-17 | 2004-05-04 | Eisai Co., Ltd. | Methods and compositions using cholinesterase inhibitors |
| EA012325B1 (ru) * | 2002-12-24 | 2009-08-28 | Беллус Хелс (Интернэшнл) Лимитед | Терапевтические составы для лечения болезней, связанных с наличием бета-амилоида |
| EP1603548A4 (en) * | 2003-02-05 | 2007-10-10 | Myriad Genetics Inc | METHOD AND COMPOSITION FOR THE TREATMENT OF NEURODEEGENERATIVE DISEASES |
| CA2516990A1 (en) * | 2003-03-19 | 2004-09-30 | Ares Trading S.A. | Treatment of alzheimer's disease |
| US20050090449A1 (en) * | 2003-05-13 | 2005-04-28 | Boehringer Ingelheim International Gmbh | Novel statine derivatives for the treatment of Alzheimer's disease |
-
2005
- 2005-04-04 MX MXPA06011969A patent/MXPA06011969A/es unknown
- 2005-04-04 AU AU2005232447A patent/AU2005232447A1/en not_active Abandoned
- 2005-04-04 CA CA002562069A patent/CA2562069A1/en not_active Abandoned
- 2005-04-04 KR KR1020067021174A patent/KR20060133008A/ko not_active Ceased
- 2005-04-04 RU RU2006136361/15A patent/RU2006136361A/ru not_active Application Discontinuation
- 2005-04-04 BR BRPI0509881-5A patent/BRPI0509881A/pt not_active IP Right Cessation
- 2005-04-04 EP EP05718393A patent/EP1737539A1/en not_active Withdrawn
- 2005-04-04 WO PCT/IB2005/000923 patent/WO2005099823A1/en not_active Ceased
- 2005-04-04 JP JP2007507862A patent/JP2007532624A/ja not_active Withdrawn
- 2005-04-04 CN CNA2005800173902A patent/CN1960781A/zh active Pending
- 2005-04-13 TW TW094111657A patent/TW200533341A/zh unknown
-
2006
- 2006-09-14 IL IL178120A patent/IL178120A0/en unknown
- 2006-10-03 ZA ZA200608239A patent/ZA200608239B/en unknown
- 2006-11-13 NO NO20065196A patent/NO20065196L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| NO20065196L (no) | 2007-01-03 |
| CN1960781A (zh) | 2007-05-09 |
| IL178120A0 (en) | 2006-12-31 |
| CA2562069A1 (en) | 2005-10-27 |
| AU2005232447A1 (en) | 2005-10-27 |
| TW200533341A (en) | 2005-10-16 |
| KR20060133008A (ko) | 2006-12-22 |
| RU2006136361A (ru) | 2008-04-20 |
| JP2007532624A (ja) | 2007-11-15 |
| EP1737539A1 (en) | 2007-01-03 |
| MXPA06011969A (es) | 2006-12-15 |
| WO2005099823A1 (en) | 2005-10-27 |
| BRPI0509881A (pt) | 2007-10-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0671171A1 (en) | Use of HMG COA reductase inhibitor for the manufacture of a medicament for proventing or reducing risks of onset of cardiovascular events | |
| Kerola et al. | The complex interplay of cardiovascular system and cognition: how to predict dementia in the elderly? | |
| KR20230159380A (ko) | 고지혈증 또는 혼합형 이상지혈증을 앓고 있는 스타틴불내성 환자에서 사용하기 위한 오비세트라피브 및 에제티미브의 조합 요법 | |
| AU2023208107A1 (en) | Composition comprising an anti-Αβ protofibril antibody and a beta- secretase BACE1 inhibitor for the treatment of Alzheimer's disease | |
| Chong | Therapeutic Controversies; Lack of Therapeutic Interchangeability of HMG-CoA Reductase Inhibitors | |
| Li et al. | Sulforaphane suppresses Aβ accumulation and tau hyperphosphorylation in vascular cognitive impairment (VCI) | |
| JP2005526806A (ja) | 認知障害の治療法 | |
| RU2388479C1 (ru) | Способ коррекции гиперхолестеринемии | |
| ZA200608239B (en) | Therapeutic combination for treatment of Alzheimers disease | |
| CA2382548C (en) | Treatment of migraine by the administration of alpha-lipoic acid or derivatives thereof | |
| CA3227153A1 (en) | Treatment of his hyporesponders | |
| Tonstad et al. | Management of hyperlipidemia in the pediatric population | |
| Kurata et al. | Cerivastatin induces carotid artery plaque stabilization independently of cholesterol lowering in patients with hypercholesterolaemia | |
| JP2007513991A (ja) | メタボリック症候群の処置のためのスタチンの使用 | |
| Fernandez et al. | The use of methylphenidate in HIV patients: A clinical perspective | |
| RU2058144C1 (ru) | Средство для лечения сердечной недостаточности | |
| Heinig et al. | Rapid attainment of steady-state acetylcholinesterase inhibition by administration of metrifonate loading and maintenance doses once-daily in elderly volunteers | |
| Goldberg et al. | 1084-174 Efficacy of ezetimibe-10 mg/day coadministered with multiple doses of simvastatin in patients with primary hypercholesterolemia | |
| CN118678950A (zh) | 用于治疗阿尔茨海默氏病的alz-801 | |
| AU2013202455B2 (en) | Methods for preventing and treating neurodegenerative diseases | |
| JP2727343B2 (ja) | サラセミア症治療剤 | |
| CN113730585A (zh) | 一种小剂量联合用治疗顽固性高血压的药物组合 | |
| JPH04112823A (ja) | 痴呆治療剤 | |
| Goldberg | The impact of lipid lowering in coronary artery disease | |
| Dastani | Assessment of drug utilization patterns, medication compliance and physician adherence to lipid and safety monitoring guidelines among patients on lipid-lowering drugs in the Texas Medicaid system |